Cryo-Cell (CCEL): רווח נקי למניה (EPS TTM)
Optimizing cryochamber energy costs as part of its ESG strategy combines with the full localization of business in the US, which eliminates external geopolitical risks. This 12-month net income per share chart visualizes the result of this stability, where -0.24 serves as the current metric level. This price action confirms the effectiveness of Cryo-Cell International (CCEL) leadership in biobanking focused on long-term cell storage for young families.
פילוחים אנליטיים ודוחות נתונים של חברת cryo-cell.com (CCEL)
Net income per share over 12 months measures the rolling annual earnings distributed per security. This metric allows for an assessment of real capital generation efficiency by excluding the impact of quarterly fluctuations. Analyzing the rolling earnings per share reveals the true growth vector of the business. For Cryo-Cell International (CCEL), such stability confirms the financial resilience of the oldest biobank in the US. Monolithic client trust converts into predictable asset returns.
